0001209191-19-041709.txt : 20190710
0001209191-19-041709.hdr.sgml : 20190710
20190710170802
ACCESSION NUMBER: 0001209191-19-041709
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190708
FILED AS OF DATE: 20190710
DATE AS OF CHANGE: 20190710
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STACK DAVID M
CENTRAL INDEX KEY: 0001204788
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 19949941
MAIL ADDRESS:
STREET 1: THE MEDICINES CO
STREET 2: 8 CAMPUS DRIVE
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-07-08
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001204788
STACK DAVID M
C/O PACIRA BIOSCIENCES, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
1
1
0
0
CEO and Chairman
Common Stock
2019-07-08
4
S
0
12415
42.85
D
156999
D
Common Stock
2019-07-08
4
S
0
700
43.42
D
156299
D
Common Stock
18596
I
By Stack Schroon Mohawk FLP
Common Stock
1208
I
By LCK Investment LLC
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.195 to $43.19, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 4.
Includes 183 shares of common stock acquired under the issuer's employee stock purchase plan in June 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.26 to $43.545, inclusive.
Mr. Stack is the general partner of Stack Schroon Mohawk FLP. Mr. Stack and his wife are the owners of LCK Investment LLC.
/s/ Kristen Williams, Attorney-in-Fact
2019-07-10